Artical Courtesy of weforum.org
How is the World Economic Forum bringing data-driven healthcare to life?
The application of “precision medicine” to save and improve lives relies on good-quality, easily-accessible data on everything
from our DNA to lifestyle and environmental factors. The opposite to a one-size-fits-all healthcare system, it has vast,
untapped potential to transform the treatment and prediction of rare diseases—and disease in general.
But there is no global governance framework for such data and no common data portal. This is a problem that contributes to the premature deaths of hundreds of millions of rare-disease patients worldwide.
The World Economic Forum’s Breaking Barriers to Health Data Governance initiative is focused on creating, testing and growing a framework to support effective and responsible access – across borders – to sensitive health data for the treatment and diagnosis of rare diseases.
The data will be shared via a “federated data system”: a decentralized approach that allows different institutions to access each other’s data without that data ever leaving the organization it originated from. This is done via an application programming interface and strikes a balance between simply pooling data (posing security concerns) and limiting access completely.
The project is a collaboration between entities in the UK (Genomics England), Australia (Australian Genomics Health Alliance), Canada (Genomics4RD), and the US (Intermountain Healthcare). Emerging technologies such as artificial intelligence (AI) and machine learning are transforming nearly
all industries, among them the healthcare industry, which accounts for 11% of global GDP or $9 trillion
annually. From the development of drugs and vaccines, to improving medical diagnosis and treatment,
such technologies are being used in all stages of the value chain, boosting efficiencies across the overall
As the World Economic Forum launches the 2023 cohort of Technology Pioneers, we asked the six selectees how such
emerging technologies are changing global health outcomes. Here is what they said:
‘Prioritizing privacy and security are essential’
Riddhiman Das, Chief Executive Officer, Tripleblind
Emerging technologies like AI and machine learning will revolutionize global health outcomes. These advancements can
improve medical diagnosis, treatment and healthcare delivery. AI algorithms can catalyse the rapid analysis of health data,
leading to precise diagnoses and timely interventions. Predictive models powered by AI can detect patterns and trends, aiding
disease prevention and personalized treatment plans.
However, prioritizing privacy and security are essential. All AI/machine learning solutions must uphold stringent privacy standards, safeguarding patient data and confidentiality. When combined with privacy-enhancing technologies, integrating AI and machine learning in healthcare holds immense promise. Responsible use, coupled with privacy protection, can transform global health, enhance patient care and bridge healthcare gaps for a healthier, more equitable world.
‘AI is expected to bring about an innovation in diet recording’
Logan Kim, Chief Executive Officer, Nuvilab
AI is having a major impact on global health, where personalized data is becoming increasingly important for preventive medicine and precision health.
AI can be used to improve productivity and efficiency by automating tasks, such as diet recording. It can also innovate the user experience by providing personalized insights and solutions. For example, Nuvilab’s AI technology can be used to analyse dietary habits and provide reports on the nutritional intake rate of each menu on personal mobile devices. Patients with chronic diseases, growing children and seniors in care facilities are especially in need of such a solution.
Diet recording in the healthcare industry is commonly operated by the 24-hour recall method, which is quite subjective and has a limited sample size. AI can be used to improve the accuracy and objectivity of diet recording, as well as lower costs. This will make AI a game changer in the field of nutrition and precision health.
AI technology is expected to bring about an innovation in diet recording, and personalized data accumulation will be possible beyond the limitations of the existing diet
data. This will open up new insights and provide better outcomes in the global health landscape.
‘We can sculpt a future where quality healthcare is not a privilege for the few’
Andrés Lawson, Chief Executive Officer, Osana
In the face of complex and pressing global health problems, emerging technologies like AI and machine learning are transformative forces poised to make healthcare more accurate, accessible and economically sustainable.
AI and automation provide operating leverage for healthcare institutions, enhancing efficiency and improving outcomes. They can potentially transform healthcare delivery, increasing the supply and scalability of healthcare professionals. For instance, AI algorithms can analyse medical imaging data to identify early signs of diseases like cancer, often with greater accuracy than human doctors and at a lower cost. This allows for earlier, more effective treatment, potentially saving millions of lives.
However, it is essential to exercise forethought to guard against unintended consequences, which means adopting a safety-first, human-first approach in the development and deployment of these models. Technical challenges like privacy, bias and reliability must be intentionally addressed. Collaboration with key ecosystem stakeholders to certify models and develop governance frameworks for Responsible Healthcare General Intelligence is vital.
As we stand on the brink of this exciting new frontier, the vision of a healthier world, buoyed by AI and machine learning, is within our grasp. These technologies hold the promise of a transformative leap in our global health landscape, enabling us to counter medical challenges with unprecedented agility and
accuracy. By harnessing AI and machine learning judiciously and responsibly, we can sculpt a future where quality healthcare is not a privilege for the few but a fundamental right for all.
‘AI and machine learning will take healthcare to the next level’
Alicia Chong, Chief Executive Officer, Bloomer Health Tech
The convergence of continuous physiological data on lifestyle and environment is quickly leading to deep phenotyping. By combining this with the power of genomics, machine learning and AI will take healthcare to the next level.
At Bloomer Tech we’ve focused on understanding the cardiovascular
system in women specifically, because even with over 30 years of evidence on sex differences, women continue to be harder to diagnose and treat, and consistently experience worse outcomes. Using AI to generate new digital biomarkers will transform this field and impact global health results, particularly for diseases and conditions that affect women disproportionately, differently and even uniquely.
Inspired by the technological transformation that resulted when we transitioned from the limitations of only being able to view photos through chemical processes and film, to enabling accessible, unlimited photos through compact, easy-to-use digital cameras, we are moving in the right direction.
We are pushing to move from existing, valuable though limited biomarkers that can only be viewed via chemical processes in labs, towards using AI trained with reliable data, continuously collected from everyday garments like women’s bras.
The impact of ubiquitous access to data will be huge. Being able to read and examine the data when it’s needed most instead of just starting a series of tests when it may already be too late will significantly impact people’s health across the world, allowing for proactive and preemptive care.
‘This is the time for computational embryology’
Daniella Gilboa, Chief Executive Officer, AIVF
IVF has revolutionized reproductive care, but it is highly dependent on expertise and experience. The most crucial dilemma in IVF is which embryo has the highest chances of becoming a healthy baby. Embryo evaluation done by experts is based on subjective human analysis.
Let’s leap to the future and consider the alternative: a machine that generates new understanding of developmental milestones, recognizing features that cannot be seen by the human eye, incorporating data from different sources, providing an outcome that’s more accurate than any human embryologist. A personalized treatment. This is the time for computational embryology, letting the machines do what we cannot and working together as a team. Alan Turing talked about machine vs. human. At AIVF we talk about a humanmachine team. Let’s team up with our AI models to do better medicine, to provide better care, to lower barriers of entry, and to allow everyone better access to the best care possible. A year ago, a miracle happened that changed IVF history. An IVF clinic reported the birth of the first IVF baby
following embryonic evaluation and selection by an AI model. It’s not a dream anymore – it’s here to stay and we should embrace it.
‘Drug development cycles are becoming more efficient with theuse of AI’
Alok Anil, Founder and CEO / Managing Director, Next Big Innovation Labs
The global health ecosystem is rapidly transitioning towards a personalized medicine-focused, outcome-based industry. Rapidly evolving biological threats like the recent COVID-19 pandemic highlight how a major overhaul is required in healthcare and pharmaceutical R&D. Emerging AI techniques can help process large data sets that pharma and healthcare industries have been capturing, and by building case-specific machine learning algorithms to streamline labour intensive processes, governments and companies save research dollars and time, while bringing efficiency to R&D processes.
MedTech devices such as 3D bioprinters with smart AI chips powering these machines to work round the clock and produce tissues on-demand could soon be the new normal towards bioprinting in tough environments like space. Pharmaceutical drug development cycles are becoming more efficient with the use of AI in early-stage drug development studies, moving towards fast-tracking to market critical lifesaving drugs that are under development.
The US Food and Drug Administration has announced its new modernization act 2.0, which enables the pharmaceutical industry to consider “cell-based assays (like 3D bio-printed tissues)” and “computer models (like AI and machine learning-based approaches)” to test for the safety and effectiveness of a drug – a big push towards building stakeholder confidence in these emerging technologies.